ClinicalTrials.gg
CompletedNCT05263245Skippy 1Updated Sep 3, 2025

The Pharmacological Effects of Using Cabozantinib With a Light Breakfast

A Phase 2 interventional study of Light breakfast in Renal Cell Carcinoma, sponsored by dr. Tom van der Hulle. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by dr. Tom van der Hulle · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Carcinoma, Renal Cell with a site in Netherlands — 10 open to participants now, 21 under way, 8 of them phase 3. Carcinoma, Renal Cell · Netherlands.

Enrollment
80th of 83
12 · median 165
Started
2023
with 2 others
Phase 2
23 of 105
1 open now
Registered
93rd of 105
by date

Among the 105 studies in Carcinoma, Renal Cell with a site in Netherlands, this one is the 80th largest by enrollment of the 83 interventional ones that give a count, is one of 3 that started in 2023, is one of 23 in phase 2, and was the 93rd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 105 studies in Carcinoma, Renal Cell with a site in Netherlands are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Carcinoma, Renal Cell with a site in Netherlands, or all of them as a file.
02

Study summary

Cabozantinib is a drug which is used to treat metastasized kidney cancer. While it works well, it has a lot of side effects and is quite expensive (€213,- every tablet, €6403,- every month). The standard recommended dose is 60 mg once a day, taken in fasted state. This means patients are not allowed to eat at least 2 hours before and one hour after taking cabozantinib. In daily practice, this is difficult for patients. It might be that by taking with breakfast the chance of side effects like nausea and diarrhea decreases. If patients take cabozantinib with breakfast, the body will have a higher uptake of the drug.

Often the dose of cabozantinib has to be lowered due to side effects. All tablets cabozantinib have the same price, despite how many milligrams are in the tablets. Cabozantinib stays in the body for a long time after ingestion. It takes approximately 120 hours before half of the medicine has left the body. This means it might not be necessary to take cabozantinib every day. Therefore, it is interesting to investigate if taking cabozantinib with breakfast makes it possible to skip taking cabozantinib once in a while. In this study, the investigators want to investigate to what extent the exposure of cabozantinib increases after ingestion with a light breakfast. The results from this study will be used for the development of alternative dosing regimens with cabozantinib tablets of 60 mg taken with a light breakfast including skipping days.

In this study, patients will randomized to start with taking cabozantinib in fasted state (standard regimen) and taking cabozantinib with a light breakfast (experimental regimen). Menu options will be provided. After at least 4 weeks taking cabozantinib according to the randomized regimen, patients will be submitted to the hospital for one day to measure the amount of cabozantinib in the blood at several points of time. This will be measured by venepuncture and fingerprick microsampling. When all blood samples have been collected, the patient will switch to the other regimen. After at least 4 weeks taking cabozantinib according to the second regimen, venous blood samples will be collected in exactly the same way. After all patients have completed the study, an analysis will be performed to determine the change in exposure to cabozantinib when it is taken with a light breakfast. The results will be used in order to determine the definitive experimental dosing regimens that will be investigated a subsequent study. Patients will be monitored for side effects, especially nausea and/or diarrhea.

The primary goal is to investigate to what extent the exposure of cabozantinib increases by taking cabozantinib with a light breakfast compared to taking cabozantinib in fasted state. The secondary objective is to investigate the analytical feasibility of microsampling (finger prick) for cabozantinib concentration measurements and to monitor side effects.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Carcinoma, Renal Cell / drug therapy
  • Cabozantinib
  • Angiogenesis Inhibitors / pharmacokinetics
  • Food-drug interactions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide ;
  • Aged 18 years or older;
  • confirmed advanced renal cell carcinoma;
  • Receiving cabozantinib as monotherapy as treatment for RCC;
  • At least 4 weeks on a stable dosage of cabozantinib;
  • Acceptable tolerability and the need for dose reductions or treatment interruptions has been estimated as low;
  • (ECOG) performance status of 0-2;
  • Estimated of ≥ 6 months;
  • No response evaluation planned during the study period;
  • Cabozantinib trough concentration ≤1125 ng/ml in steady state

Exclusion criteria

Exclusion Criteria:

  • Inability to follow the recommended light breakfast;
  • Gastro-intestinal abnormalities influencing the absorption of cabozantinib, including active inflammatory bowel diseases, malabsorption syndrome and prior major surgery of the stomach, pancreas, liver or smaller bowel.
  • Use of moderate or strong inhibitor of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including ketoconazole, grape fruit juice, clarithromycin, erythromycin, itraconazole and ritonavir.
  • Use of moderate or strong inducer of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including rifampicin, phenytoin, carbamazepine, phenobarbital and herbal preparations containing St. John's Wort.
  • Use of inhibitor of multidrug resistance-associated protein 2 within 1 month of start of treatment with cabozantinib, including cyclosporine, delavirdine, efavirenz, emtricitabine, benzbromarone and probenecid.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • No intervention
    Standard regimen

    Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study.

  • Experimental
    Experimental regimen

    Patients will take the prior recommended dose cabozantinib with a light breakfast.

    Other: Light breakfast

Interventions

  • OtherLight breakfast

    Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.

This study also gives CabozantinibStudies of CabozantinibCabozantinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC)

    Increase of the area under the concentration-time curve (AUC) of the experimental regimen compared to the standard regimen

    Time frame: At both hospital admissions after at least 28 days on the regimen (t = 0, 1, 2, 3, 4, 5, 6, 8 and 24 hours)

Secondary outcomes

  1. Analytical feasibility

    Analytical correlation/agreement between venapuncture (plasma) measurements and microsampling (whole blood and capillary plasma) measurements

    Time frame: At both hospital admissions after at least 28 days on the regimen (t = 0, 1, 2, 3, 4)

  2. Adverse events

    The total number of patients experiencing (S)AEs

    Time frame: At inclusion and at both hospital admissions after at least 28 days on the regimen

07

Study locations

2 sites
  • Leids Universitair Medisch Centrum
    Leiden, South Holland 2333 ZA, Netherlands
  • Erasmus Medical Center
    Rotterdam, South Holland 3015 GD, Netherlands
08

References and documents

Publications

  • Rieborn A, Guchelaar NAD, van Gelder T, Gelderblom H, Luelmo SAC, Kerssemakers N, Hamberg PAP, Koolen SLW, Mathijssen RHJ, Moes DJAR, van der Hulle T. The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1). Clin Pharmacokinet. 2026 Mar;65(3):431-439. doi: 10.1007/s40262-025-01612-2. Epub 2026 Jan 19. PubMed 41555108 ↗

Individual participant data

Plan to share: Undecided — To be determined in detail

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2025, 21 months.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 21 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Mar 2, 2022
StartActual
May 25, 2023
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 11, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05263245
Lead sponsor
dr. Tom van der Hulle
Responsible party
dr. Tom van der Hulle (Principal Investigator, Leiden University Medical Center) — Sponsor-investigator
First posted
Mar 2, 2022
Start date
May 25, 2023
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025
Last update
Sep 3, 2025

Study contacts

Tom van der Hulle, MD PhD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion